Strikingly, numerous clinical trials have concluded that SGLT2 inhibitors (SGLT2is) have benefits beyond glucose regulation, including improved outcomes in heart failure patients and slower progression of chronic kidney disease in patients with or without T2D.10 Here, SLC5A2 is linked to type 2 diabetes mellitus.